Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC2 | Q13490 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 17/20 | 0.47 |
| ▸ | MMP3 | P08254 | 12/20 | 0.47 |
| ▸ | MMP1 | P03956 | 10/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MMP7 | P09237 | 6/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL130361 | 1.00 | BIRC2 (0.47) | BIRC2MMP2MMP3MMP1CNR2 | |
| SCHEMBL13681826 | 0.96 | NPC1 (0.47) | BIRC2MMP2MMP3MMP1CNR2 | |
| SCHEMBL3859822 | 0.96 | NPC1 (0.47) | BIRC2MMP2MMP3MMP1CNR2 | |
| SCHEMBL3901123 | 0.84 | CNR2 (0.48) | BIRC2MMP2MMP1CNR2NPC1 | |
| SCHEMBL3944730 | 0.84 | NPC1 (0.43) | MMP3MMP1NPC1RAB9A | |
| SCHEMBL16898305 | 0.83 | NPC1 (0.50) | CNR2NPC1RAB9A | |
| SCHEMBL16898303 | 0.83 | NPC1 (0.50) | CNR2NPC1RAB9A | |
| SCHEMBL4392476 | 0.82 | NPC1 (0.43) | NPC1RAB9A | |
| SCHEMBL4392472 | 0.82 | NPC1 (0.43) | NPC1RAB9A | |
| SCHEMBL13681824 | 0.82 | CTSL (0.41) | BIRC2MMP2MMP3MMP1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363873-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2016-04-20 | — | — | EP | disclosed |
| EP-1585518-B9 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-08-08 | — | — | EP | disclosed |
| EP-1585757-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-1585518-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-03-07 | — | — | EP | disclosed |
| US-7919528-B2 | Antibiotic; bactericides | GLAXOSMITHKLINE LLC (US) | 2011-04-05 | — | — | US | disclosed |
| EP-1585757-A4 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2009-04-22 | — | — | EP | disclosed |
| EP-1585518-A4 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2009-04-22 | — | — | EP | disclosed |
| EP-1615629-B1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2009-03-18 | — | — | EP | disclosed |
| US-7442793-B2 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-28 | — | — | US | disclosed |
| US-7375120-B2 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-20 | — | — | US | disclosed |
| EP-1585518-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20050222412-A1 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC | 2005-10-06 | — | — | US | disclosed |
| WO-2005032550-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-04-14 | — | — | WO | disclosed |
| EP-1509218-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SmithKline Beecham Corporation (US) | 2005-03-02 | — | — | EP | disclosed |
| WO-2004098584-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-11-18 | — | — | WO | disclosed |
| WO-2004052919-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-06-24 | — | — | WO | disclosed |
| US-20040087585-A1 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC | 2004-05-06 | — | — | US | disclosed |
| WO-2003101442-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-11 | — | — | WO | disclosed |
| EP-1363873-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SmithKline Beecham Corporation (US) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002070541-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SMITH KLINE BEECHAM CORPORATION (US) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087585-A1 | Peptide deformylase inhibitors | PDF, DPEP1, PEPD | BIRC2 3366/4885MMP2 545/4885MMP3 1114/4885 |
| US-20050222412-A1 | Peptide deformylase inhibitors | PDF, PEPD, DPEP1 | BIRC2 2594/4885MMP2 857/4885MMP3 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.